Flex Pharma Inc (NASDAQ:FLKS) – Stock analysts at Jefferies Group issued their Q1 2018 earnings estimates for shares of Flex Pharma in a note issued to investors on Thursday. Jefferies Group analyst M. Andrews anticipates that the biotechnology company will post earnings of ($0.45) per share for the quarter. Jefferies Group also issued estimates for Flex Pharma’s Q2 2018 earnings at ($0.50) EPS, Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.29) EPS and FY2018 earnings at ($1.67) EPS.
Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald reiterated a “hold” rating and issued a $6.00 price target on shares of Flex Pharma in a report on Wednesday, March 7th. Zacks Investment Research upgraded Flex Pharma from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. Ladenburg Thalmann Financial Services began coverage on Flex Pharma in a report on Thursday, January 25th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Roth Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Flex Pharma in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.55.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.10. Flex Pharma had a negative return on equity of 85.02% and a negative net margin of 2,698.59%. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.36 million.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Granite Point Capital Management L.P. increased its holdings in Flex Pharma by 80.8% during the 4th quarter. Granite Point Capital Management L.P. now owns 71,520 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 31,961 shares during the period. Renaissance Technologies LLC increased its holdings in Flex Pharma by 67.1% during the 4th quarter. Renaissance Technologies LLC now owns 89,900 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 36,100 shares during the period. Ameriprise Financial Inc. increased its holdings in Flex Pharma by 10.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock worth $2,457,000 after purchasing an additional 65,699 shares during the period. Finally, Sphera Funds Management LTD. increased its holdings in Flex Pharma by 70.7% during the 4th quarter. Sphera Funds Management LTD. now owns 241,211 shares of the biotechnology company’s stock worth $4,339,000 after purchasing an additional 99,911 shares during the period. Hedge funds and other institutional investors own 28.96% of the company’s stock.
WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3258651/flex-pharma-inc-flks-expected-to-post-q1-2018-earnings-of-0-45-per-share.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.